Kronos Bio, Inc. (KRON): History, Ownership, Mission, How It Works & Makes Money

Kronos Bio, Inc. (KRON): History, Ownership, Mission, How It Works & Makes Money

US | Healthcare | Biotechnology | NASDAQ

Kronos Bio, Inc. (KRON) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Interested in how biotech companies are tackling cancer and autoimmune diseases? What if there was a company dedicated to discovering and developing novel therapies by targeting the very source of these diseases: deregulated transcription? This blog post dives into Kronos Bio, Inc. (KRON), a clinical-stage biopharmaceutical company, to explore its history, ownership, mission, how it operates, and its revenue model, especially in light of its $47.56 million market cap as of April 2025. Keep reading to understand how Kronos Bio is trying to transform patient outcomes through precision medicine.

Kronos Bio, Inc. (KRON) History

[Company's] Founding Timeline

Year established

The company was established in 2017.

Original location

The company's original location is San Mateo, California.

Founding team members

The founding team included:

  • Norbert Bischofberger
  • Arthur Sands

Initial capital/funding

In October 2017, the company completed a $18 million Series A financing round led by Vida Ventures and Omega Funds.

[Company's] Evolution Milestones

Year Key Event Significance
2017 Series A Financing

Raised $18 million, enabling initial research and development activities.

2019 Series B Financing

Closed a $105 million Series B financing to advance pipeline programs.

2020 Acquisition of GenEdit's pre-clinical compound

Expanded the pipeline with a compound targeting MYC, a key cancer driver.

2020 Initial Public Offering (IPO)

Began trading on the Nasdaq Global Select Market under the ticker symbol 'KRON'.

2021 Initiation of Phase 1/2 Clinical Trial of KB-0742

Marked a significant step in clinical development, evaluating KB-0742 in transcriptionally addicted solid tumors.

2024 Restructuring and Pipeline Prioritization

Implemented a restructuring plan to focus on clinical programs, including discontinuing the development of lanraplenib.

[Company's] Transformative Moments

The company has undergone several transformative moments that have shaped its trajectory:

  • Focus on Transcription Factor Modulation: The company's strategic focus on developing therapies that modulate transcription factors, which are key regulators of gene expression, has been central to its approach to targeting difficult-to-drug targets in cancer.
  • Pipeline Prioritization: In 2024, the company made a significant decision to discontinue the development of lanraplenib and prioritize its clinical programs, particularly KB-0742. This decision reflected a strategic shift towards focusing resources on the most promising assets in its pipeline.
  • Clinical Development of KB-0742: The advancement of KB-0742 into clinical trials represents a major milestone for the company. This compound, which targets transcriptionally addicted solid tumors, has the potential to address significant unmet needs in cancer treatment.

Learn more about the company's investors: Exploring Kronos Bio, Inc. (KRON) Investor Profile: Who’s Buying and Why?

Kronos Bio, Inc. (KRON) Ownership Structure

Kronos Bio, Inc. operates with a mixed ownership structure, featuring a combination of institutional, insider, and retail investors, influencing its strategic decisions and corporate governance.

Kronos Bio, Inc.'s Current Status

Kronos Bio, Inc. is a public company, trading on the Nasdaq Global Select Market under the ticker symbol KRON. This status allows it to raise capital through public offerings and subjects it to regulatory oversight by the Securities and Exchange Commission (SEC).

Kronos Bio, Inc.'s Ownership Breakdown

Understanding the ownership structure of Kronos Bio, Inc. provides insights into who has the most significant influence on the company. Here's a breakdown of the ownership composition:

Shareholder Type Ownership, % Notes
Institutional Investors 68.54% These are firms that manage money on behalf of others, such as mutual funds, pension funds, and hedge funds. Their holdings can significantly influence stock price and company policy.
Insider Ownership 3.07% This includes the company's officers and directors, who have direct knowledge of the company's operations and prospects. Their ownership aligns their interests with those of shareholders.
Retail Investors 28.39% These are individual investors who buy and sell securities for their own accounts. A large retail investor base can provide stability but may also increase volatility.

Kronos Bio, Inc.'s Leadership

The leadership team at Kronos Bio, Inc. is responsible for the strategic direction and operational execution of the company. Key members include:

  • Norbert G. Bischofberger, Ph.D. serves as the President and Chief Executive Officer.
  • Jordi Camps, M.B.A. is the Chief Financial Officer.
  • Jorge DiMartino, M.D., Ph.D. holds the position of Chief Medical Officer & EVP, Clinical Development.

These individuals, along with other members of the executive team, guide Kronos Bio in its mission to develop and commercialize innovative cancer therapies.

For more detailed insights into the ownership dynamics and investor profiles, check out: Exploring Kronos Bio, Inc. (KRON) Investor Profile: Who’s Buying and Why?

Kronos Bio, Inc. (KRON) Mission and Values

Kronos Bio is dedicated to developing innovative therapies that target dysregulated transcription factors and the gene regulatory network to transform the lives of patients with cancer and other serious diseases. The company values scientific rigor, innovation, collaboration, and a patient-centric approach.

Kronos Bio's Core Purpose

Official mission statement

Kronos Bio's mission statement is to 'transform the lives of patients with cancer and other serious diseases by discovering and developing innovative therapies that target dysregulated transcription factors and the gene regulatory network.'

  • Focuses on developing therapies for cancer and other serious diseases.
  • Aims to create innovative treatments by targeting transcription factors and the gene regulatory network.
  • Strives to improve patient outcomes and quality of life.

To learn more about the investors, read this article: Exploring Kronos Bio, Inc. (KRON) Investor Profile: Who’s Buying and Why?

Vision statement

While Kronos Bio does not have a specific, publicly declared vision statement, their actions and focus suggest a vision to:

  • Become a leader in the field of transcription factor-targeted therapies.
  • Successfully translate scientific discoveries into clinically meaningful treatments.
  • Establish a sustainable pipeline of innovative drug candidates.

Company slogan/tagline

Kronos Bio does not have an official, widely publicized slogan or tagline. However, considering their mission and focus, a possible implied tagline could be:

  • 'Targeting the Source, Transforming Lives.'
  • 'Innovating Transcription Factor Therapies.'
  • 'Unlocking the Potential of Gene Regulation.'

Kronos Bio, Inc. (KRON) How It Works

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that target dysregulated transcription factors and the gene regulatory network to transform the lives of patients with cancer and other serious diseases.

Kronos Bio's Product/Service Portfolio

Product/Service Target Market Key Features
Entospletinib Relapsed or Refractory Acute Myeloid Leukemia (AML) patients with NPM1 mutations Selective spleen tyrosine kinase (SYK) inhibitor designed to target genetically defined AML. Phase 3 trial ongoing.
Lanraplenib Patients with relapsed or refractory FLT3-mutated AML Next-generation FLT3 inhibitor, designed to be potent and selective, addressing a key resistance mechanism to prior FLT3 inhibitor therapies. Phase 1/2 trial ongoing.

Kronos Bio's Operational Framework

Kronos Bio operates through a research and development model focused on novel cancer therapies. Key aspects of their operational framework include:

  • Drug Discovery and Development: Kronos Bio focuses on discovering and developing innovative therapies targeting deregulated transcription factors and the gene regulatory network.
  • Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates. For instance, they are currently running a Phase 3 trial for entospletinib and a Phase 1/2 trial for lanraplenib.
  • Partnerships and Collaborations: Kronos Bio may engage in strategic partnerships and collaborations to enhance its research and development efforts.
  • Financial Management: Effective financial planning and resource allocation are essential to support ongoing research and development activities. As of the fiscal year 2023, Kronos Bio reported a net loss of $98.1 million, reflecting significant investment in its clinical programs. The company's financial strategy includes managing cash reserves, which totaled $141.2 million as of December 31, 2023, to fund operations into the second half of 2025.

More insights about Kronos Bio can be found here: Mission Statement, Vision, & Core Values of Kronos Bio, Inc. (KRON).

Kronos Bio's Strategic Advantages

Kronos Bio's strategic advantages include:

  • Targeted Therapies: Focus on genetically defined AML subgroups, increasing the likelihood of clinical success.
  • Novel Approach: Targeting dysregulated transcription offers a unique approach to cancer treatment.
  • Experienced Team: A management team with a proven track record in drug development.

Kronos Bio, Inc. (KRON) How It Makes Money

Kronos Bio, Inc. operates as a clinical-stage biopharmaceutical company, primarily focused on discovering and developing therapies targeting dysregulated transcription factors and the deregulated genome to treat cancer and other serious diseases.

Kronos Bio, Inc.'s Revenue Breakdown

As a clinical-stage biopharmaceutical company, Kronos Bio, Inc. currently does not generate revenue from product sales. Its primary source of funding comes from strategic collaborations, licensing agreements, and investments. Revenue streams for such companies are typically realized upon successful clinical development, regulatory approval, and subsequent commercialization of their drug candidates.

Revenue Stream % of Total Growth Trend
Collaboration and Licensing Agreements 100% Variable, dependent on new agreements
Product Sales 0% N/A until commercialization

Kronos Bio, Inc.'s Business Economics

The business economics of Kronos Bio, Inc. are characterized by significant upfront research and development (R&D) costs, typical of a biotechnology firm. These costs include:

  • Drug discovery and preclinical studies.
  • Clinical trial expenses (Phase 1, 2, and 3).
  • Regulatory approval processes.

The company's profitability is contingent upon the successful development and commercialization of its drug candidates. Key economic factors include:

  • Market size: The prevalence and incidence of the specific cancers targeted by their therapies.
  • Pricing and reimbursement: The ability to secure favorable pricing and reimbursement from healthcare providers and insurance companies.
  • Competition: The presence of competing therapies and their relative efficacy and safety profiles.

Kronos Bio, Inc. relies on intellectual property protection (patents) to maintain a competitive advantage and secure market exclusivity for its drug candidates.

Kronos Bio, Inc.'s Financial Performance

Kronos Bio Inc.'s financial performance can be assessed through various key metrics. According to their 2024 financial results, the company reported:

  • Cash Position: As of December 31, 2024, Kronos Bio had cash, cash equivalents, and marketable securities totaling $124.2 million.
  • Research and Development Expenses: For the year ended December 31, 2024, Research and development expenses were $59.5 million.
  • General and Administrative Expenses: For the year ended December 31, 2024, General and administrative expenses were $22.9 million.
  • Net Loss: Kronos Bio reported a net loss of $77.1 million for the year ended December 31, 2024.

These figures highlight the company's ongoing investment in research and development, reflecting its stage as a clinical-stage biopharmaceutical company. The cash position is crucial for funding ongoing clinical trials and operations. These metrics provide a snapshot of the company's financial health and its capacity to fund future growth and development initiatives. For more insights into Kronos Bio, Inc., check out: Exploring Kronos Bio, Inc. (KRON) Investor Profile: Who’s Buying and Why?

Kronos Bio, Inc. (KRON) Market Position & Future Outlook

As of April 2025, Kronos Bio is strategically positioned within the competitive landscape of pharmaceutical companies focused on developing innovative cancer therapies. The company's future success depends on clinical trial outcomes, regulatory approvals, and successful commercialization of its drug candidates.

Competitive Landscape

Company Market Share, % Key Advantage
Kronos Bio Confidential Focus on dysregulated transcription and developing therapies that target historically undruggable targets.
Novartis Confidential Extensive portfolio of oncology drugs and established global presence.
Gilead Sciences Confidential Strong position in hematological malignancies with innovative cell therapies.

Opportunities & Challenges

Opportunities Risks
Potential for breakthrough therapies addressing unmet needs in cancer treatment. Clinical trial failures or delays in regulatory approvals.
Strategic collaborations with larger pharmaceutical companies. Competition from established players in the oncology market.
Expansion of pipeline through internal discovery and external partnerships. Reliance on key personnel and ability to attract and retain talent.

Industry Position

  • Kronos Bio is a clinical-stage biopharmaceutical company.
  • It is focused on discovering and developing novel therapies that target dysregulated transcription factors and the disease-driving genes and pathways within them.
  • The company's pipeline includes compounds.
  • These compounds are designed to address historically undruggable targets in cancer.

To gain more insights into the foundational principles guiding the company, explore: Mission Statement, Vision, & Core Values of Kronos Bio, Inc. (KRON).

DCF model

Kronos Bio, Inc. (KRON) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.